S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:AVEO

AVEO Pharmaceuticals Stock Forecast, Price & News

$8.18
+0.03 (+0.37 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.41
Now: $8.18
$8.24
50-Day Range
$7.79
MA: $8.45
$9.56
52-Week Range
$2.23
Now: $8.18
$10.71
Volume847,925 shs
Average Volume469,863 shs
Market Capitalization$235.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. It has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
AVEO Pharmaceuticals logo

Headlines

AVEO Oncology Highlights Recent Progress and 2021 Outlook
January 7, 2021 |  finance.yahoo.com
Is AVEO A Good Stock To Buy Now?
December 7, 2020 |  finance.yahoo.com
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
November 3, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone857-400-0101
Employees19
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.80 million
Cash Flow$0.58 per share
Book Value$0.92 per share

Profitability

Net Income$9.39 million
Net Margins-483.99%

Miscellaneous

Market Cap$235.66 million
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

863rd out of 1,972 stocks

Pharmaceutical Preparations Industry

411th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.18
+0.03 (+0.37 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

Is AVEO Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVEO Pharmaceuticals stock.
View analyst ratings for AVEO Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than AVEO Pharmaceuticals?

Wall Street analysts have given AVEO Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AVEO Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 739,500 shares, an increase of 21.5% from the January 14th total of 608,500 shares. Based on an average daily volume of 399,400 shares, the short-interest ratio is currently 1.9 days. Currently, 3.0% of the company's shares are short sold.
View AVEO Pharmaceuticals' Short Interest
.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for AVEO Pharmaceuticals
.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.09. The biopharmaceutical company had revenue of $3.60 million for the quarter, compared to analysts' expectations of $3.81 million. AVEO Pharmaceuticals had a negative net margin of 483.99% and a negative trailing twelve-month return on equity of 103.66%.
View AVEO Pharmaceuticals' earnings history
.

How has AVEO Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

AVEO Pharmaceuticals' stock was trading at $3.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AVEO stock has increased by 134.4% and is now trading at $8.18.
View which stocks have been most impacted by COVID-19
.

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for AVEO?

5 brokerages have issued 12-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $9.00 to $26.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $16.20 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts' price targets for AVEO Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the following people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 56, Pay $854.4k)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 61, Pay $597.64k)
  • Mr. Erick J. Lucera CPA, CFA, Chief Financial Officer (Age 53)
  • Ms. Lisa M. Bruneau, VP of Financial Accounting & Reporting and Treasurer (Age 54)
  • Dr. Emile Farhan, Sr. VP of Technical Operations & Quality Assurance
  • Mr. Kevin Peacock, VP of Marketing
  • Mr. David Crist, VP of Sales
  • Ms. Catherine DeRose, VP of HR
  • Mr. Mike Ferraresso, Sr. VP of Bus. Analytics & Commercial Operations

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals CEO Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among AVEO Pharmaceuticals' employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.44%), Northern Trust Corp (0.84%), Squarepoint Ops LLC (0.38%), JPMorgan Chase & Co. (0.37%), Renaissance Technologies LLC (0.33%) and Nuveen Asset Management LLC (0.28%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Fu Growth, Michael P Bailey and Peter W Sonsini.
View institutional ownership trends for AVEO Pharmaceuticals
.

Which institutional investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN.
View insider buying and selling activity for AVEO Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying AVEO Pharmaceuticals stock?

AVEO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, JPMorgan Chase & Co., Opaleye Management Inc., Trexquant Investment LP, Squarepoint Ops LLC, Dimensional Fund Advisors LP, M&T Bank Corp, and Nuveen Asset Management LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Fu Growth, Michael P Bailey, and Peter W Sonsini.
View insider buying and selling activity for AVEO Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $8.18.

How much money does AVEO Pharmaceuticals make?

AVEO Pharmaceuticals has a market capitalization of $235.66 million and generates $28.80 million in revenue each year. The biopharmaceutical company earns $9.39 million in net income (profit) each year or $0.61 on an earnings per share basis.

How many employees does AVEO Pharmaceuticals have?

AVEO Pharmaceuticals employs 19 workers across the globe.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is www.aveooncology.com.

Where are AVEO Pharmaceuticals' headquarters?

AVEO Pharmaceuticals is headquartered at 30 WINTER STREET, BOSTON MA, 02108.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 857-400-0101 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.